# Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada

> **NCT02585401** · — · COMPLETED · sponsor: **Bayer** · enrollment: 99 (actual)

## Conditions studied

- Age-related Macular Degeneration (AMD)
- Central Retinal Vein Occlusion (CRVO)
- Diabetic Macular Edema (DME)

## Interventions

- **DRUG:** Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)

## Key facts

- **NCT ID:** NCT02585401
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-18
- **Primary completion:** 2016-03-31
- **Final completion:** 2016-05-19
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2017-03-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02585401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02585401, "Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02585401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*